(Press-News.org) A new AI tool that could help doctors assess the early signs of dementia and Alzheimer’s more quickly and efficiently, has been developed by researchers at the University of Sheffield.
The system, known as CognoSpeak, uses a virtual agent displayed on a screen to engage a patient in a conversation. It asks memory-probing questions inspired by those used in outpatient consultations and conducts cognitive tests, such as picture descriptions and verbal fluency tests.
The tool then uses artificial intelligence and speech technology to analyse language and speech patterns to look for signs of dementia, Alzheimer’s disease and other memory disorders.
Researchers behind the technology say CognoSpeak could play a key role in reducing the burden on dementia assessment services, once further testing in GP and secondary care memory clinics across the UK is complete.
The system is being designed to work in between primary and secondary care. This means that once fully rolled out, a GP could refer a person with memory complaints to use the technology. CognoSpeak would send the test results back to the GP and then they would decide whether they need to refer the patient to a memory clinic for further assessment.
CognoSpeak can be accessed through a web browser - meaning patients are able to take the test in the comfort of their home via a computer, laptop or tablet, rather than having to wait for a hospital appointment to take a pen-and-paper-based assessment, which can often cause undue stress and anxiety.
Early trials have shown the technology is as accurate at predicting Alzheimer’s as the current pen-and-paper-based tests used to assess or screen for cognitive, memory or thinking impairments. The team has demonstrated accuracies of 90 per cent for distinguishing people with Alzheimer’s from people that are cognitively healthy.
Developed by Dr Dan Blackburn and Professor Heidi Christensen from the University of Sheffield’s Departments of Neuroscience and Computer Science, the CognoSpeak system is still in the research phase, but thanks to a £1.4 million grant from the National Institute for Health and Care Research (NIHR), the technology is being trialled more widely. The researchers are recruiting 700 participants from memory clinics across the UK to help develop the system further.
Dr Dan Blackburn, from the University of Sheffield’s Department of Neuroscience, said: “Waiting for a possible diagnosis of dementia can be a very anxious time for patients and their families. This tool could help patients start treatments sooner, reduce waiting times and give people certainty earlier.
“The CognoSpeak system could transform how dementia and other memory disorders are diagnosed by speeding up assessments. This would also free-up clinicians’ valuable time and mean that those who need specialist care get access to it as quickly as possible.”
Professor Heidi Christensen from the University of Sheffield’s Department of Computer Science, said: “The way a person speaks can tell us a great deal about their cognitive health and emotional wellbeing, and give us a very early indication of any signs of cognitive decline that may not otherwise have been detected. The system we’ve developed here at Sheffield uses speech technology to automatically extract these signs and the automation means we can provide a consistent, accurate and fast assessment for everyone.
“CognoSpeak is advanced, high tech and based on world leading research in this field. We have the biggest collection of data for this type of assessment anywhere in the world, which we’re using to advance the technology and improve its accuracy.”
The CognoSpeak tool has been developed in collaboration with Therapy Box - a company specialising in speech and language technology - and the National Institute for Health and Care Research (NIHR) Devices for Dignity MedTech Cooperative (D4D), who are leading work with patients, families and ethnic minority community groups to ensure that the AI is acceptable, reliable and accessible for all future users.
The research team is also working to make the tool accessible to patients from ethnic minority communities who are less likely to engage with dementia services and who may speak English as an additional language.
Lise Sproson, Patient and Public Involvement Lead at D4D said: “We are working closely with a broad range of community groups, including Sheffield’s Israac Somali Community Association, to co-develop the look and feel of the CognoSpeak system, to ensure it is acceptable, relatable and easy to use.
“We are training the AI with a range of regional UK accents and those speaking English as an additional language, in order to maintain the accuracy it has previously demonstrated on tests with native English speakers across the population as a whole.”
Dr Blackburn, who is also an Honorary Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust and researcher at NIHR Sheffield BRC, added: “There is a real clinical need for this kind of technology. There are long waiting lists for memory clinics across the UK, but there are also inequalities in accessing the memory clinics service. The CognoSpeak tool can reduce these inequalities and help make the service more efficient.”
There are currently around 900,000 people in the UK living with dementia, and this is projected to almost double by 2040, according to the Alzheimer's Society. Referrals for assessment are increasing rapidly and memory clinics often have long waiting lists.
Professor Mike Lewis, Director of NIHR's i4i Programme, said "Cognospeak is an innovative example of how digital health technology can transform the way we tackle conditions like dementia, helping to find ways to make it easier to find and assess patients to ensure they get access to the right treatment and support"
Patients are being recruited to the CognoSpeak trial through memory clinics across the UK. To take part in the trial, visit www.cognospeak.com
END
AI tool could speed up dementia diagnosis
2023-06-29
ELSE PRESS RELEASES FROM THIS DATE:
Icahn School of Medicine at Mount Sinai researchers awarded $15.1 million grant to explore immune rejection of transplanted organs
2023-06-28
New York, NY (June 28, 2023)–Striving to improve organ transplant survival rates, internationally renowned researchers in immunology and bioengineering at the Icahn School of Medicine at Mount Sinai have received $15.1 million from the National Institute of Allergy and Infectious Diseases (NIAID) to lead a novel, five-year multi-center research program that will explore trained immunity—the innate immune system’s ability to remember infections and other insults—as a target for preventing organ transplant rejection.
Each ...
Zapping municipal waste helps recover valuable phosphorus fertilizer
2023-06-28
One of humankind’s most precious fertilizers is slipping away.
Phosphorus, which today comes mostly from nonrenewable reserves of phosphate rock, typically winds up in municipal waste streams. In the best cases, wastewater treatment plants sequester about 90% of that phosphorus in “sludge” and decompose that sludge into something known as digestate. Engineers hope to establish a more sustainable cycle for reusing phosphorus, but toxic compounds in digestate limit the possibility of recycling it as fertilizer — it’s hard to recover phosphorus from solid waste like digestate.
“Existing ...
For type 2 diabetics who exercise, some approaches are better than others
2023-06-28
An analysis on the positive effects of exercise on blood sugar levels in people with Type 2 diabetes shows that while all exercise helps, certain activities – and their timing – are extremely good for people’s health.
The study, published in The American Journal of Medicine, provides a comprehensive but straightforward summary of the benefits of exercise on controlling blood glucose levels in people with Type 2 diabetes.
“The challenge with this is that most, if not all, people know exercise is good for them but they don’t know the best approach,” said Steven Malin, an associate professor in the Department of Kinesiology and Health at the Rutgers ...
Bjornsti begins her term as president of FASEB
2023-06-28
BIRMINGHAM, Ala. – Mary-Ann Bjornsti, Ph.D., professor and former chair of the Department of Pharmacology and Toxicology at the University of Alabama at Birmingham, begins her term July 1 as president of the largest coalition of biological and biomedical research associations in the United States, the Federation of American Societies for Experimental Biology, also known as FASEB.
Bjornsti, the Newman H. Waters Chair of Clinical Pharmacology, has served as associate director for Translational Research at the O’Neal ...
Population Council joins feminist partners to advance gender equality and equity at Women Deliver 2023
2023-06-28
June 28, 2023—Population Council experts and our partners at Women Deliver (WD2023) in Kigali, Rwanda will share how we can collectively build evidence-based solutions to achieve gender equality and equity. The Council will lead the Girls Deliver: Pre-Conference on Adolescent Girls and key high-profile events on the sidelines of WD2030 to advance global discourse of the linkages between gender equality with pressing issues such as adolescents, education, and climate.
“The Council is thrilled to collaborate with youth, global activist, feminist, political, and research leaders to cultivate an ecosystem ...
New drug application doubles rates of remission in patients with Ulcerative Colitis
2023-06-28
A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis. With the clinical trial demonstrating a doubling in the rates of remission, to up to 50%, in certain groups. The results of this clinical trial are, today, published in the New England Journal of Medicine.
Around the world, it is estimated that millions live with ulcerative colitis, a condition that is only growing in prevalence. Geert D’Haens, lead author and Professor of Gastroenterology at Amsterdam UMC, says “there is still a high unmet need for safe and effective treatments for ulcerative colitis. This new medicine meets this ...
New approach in cancer therapy with innovative mechanism-of-action for ferroptosis induction
2023-06-28
A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis. Ferroptosis is characterized by the iron-dependent oxidative destruction of cellular membranes, which is counteracted by ferroptosis suppressor protein-1 (FSP1), one of the guardians of ferroptosis. Although FSP1 has been considered as an attractive drug target for cancer therapy, in vivo efficacious FSP1 inhibitors have been lacking. To this end, the team carefully evaluated hits from a screen of around ten thousand small molecule compounds and identified icFSP1 as a new in vivo effective drug. Importantly, the team ...
Neutrons look inside working solid-state battery to discover its key to success
2023-06-28
Neutrons look inside working solid-state battery to discover its key to success
Researchers at the Department of Energy’s Oak Ridge National Laboratory were the first to use neutron reflectometry to peer inside a working solid-state battery and monitor its electrochemistry. They discovered that its excellent performance results from an extremely thin layer, across which charged lithium atoms quickly flow as they move from anode to cathode and blend into a solid electrolyte.
“We want better batteries,” said ORNL’s Andrew Westover, who co-led a study published in ACS Energy Letters with James Browning at the lab’s Spallation Neutron ...
Acutely exposed to changing climate, many Greenlanders do not blame humans
2023-06-28
A new survey shows that the largely Indigenous population of Greenland is highly aware that the climate is changing, and far more likely than people in other Arctic nations to say they are personally affected. Yet, many do not blame human influences—especially those living traditional subsistence lifestyles most directly hit by the impacts of rapidly wasting ice and radical changes in weather. The study appears this week in the journal Nature Climate Change.
"Greenland is off the charts when it comes to the proportion of people who are seeing and personally experiencing the effects of climate change. But there is a big mismatch between ...
AnalySwift receives nearly $800,000 NASA contract to improve simulation of next-generation composites
2023-06-28
WEST LAFAYETTE, Ind. – NASA has awarded a $799,954 Phase II STTR contract to AnalySwift LLC, a Purdue University-affiliated commercial software provider. The company will develop DATC, or Design tool for Advanced Tailorable Composites, and launch it at the end of the two-year contract.
Allan Wood, AnalySwift president and CEO, said advancements in simulation capabilities have not always kept pace with those in manufacturing techniques. He said DATC will significantly improve NASA’s capabilities to design and analyze aerospace structures made from advanced tailorable composites.
“DATC will be used to design next-generation aerospace structures, such as hybrid/blended ...